11/11 Lecture

Pathology of Glycogen Metabolism

  • Pathological consequences of defective glycogen metabolism:

    • Inborn errors and diseases arise from the genetic inability to properly synthesize or degrade glycogen.

    • These metabolic disorders stem from loss-of-function mutations in essential enzymes governing glycogen synthesis, branching, debranching, and breakdown.

  • Primary organ systems and tissues affected:

    • Liver tissue: The liver serves as the central metabolic hub for maintaining systemic blood glucose homeostasis through glycogen synthesis (glycogenesis) and breakdown (glycogenolysis).

    • Muscle tissue: Skeletal muscle maintains extensive glycogen stores dedicated to generating intracellular energy to fuel muscle contraction.

    • Due to the concentrated reliance of liver and muscle on glycogen turnover, clinical manifestations of glycogen storage diseases localize predominantly to these two tissues.

  • Enzymes implicated in glycogen storage pathologies:

    • Glycogen synthase

    • Branching enzyme

    • Debranching enzyme

    • Glycogen phosphorylase

  • Clinical presentation in pediatric development:

    • Newborn infants with mutations in these enzymes exhibit impaired physical growth.

    • Affected infants consistently fail to reach standard developmental milestones at expected normal rates.

Principles of Reciprocal Regulation in Glycogen Metabolism

  • Necessity of reciprocal regulation:

    • Cells must coordinate metabolic flux so that glycogen synthesis is activated while glycogen degradation is simultaneously inhibited, and vice versa.

    • Simultaneous, uncontrolled activity of both opposing pathways would cause futile energy consumption without net physiological work.

  • Targeted regulatory control points:

    • Glycogen metabolism is carried out by a small number of dedicated enzymes.

    • Shared bidirectional enzymes, such as phosphoglucomutase (which reversibly converts glucose 1-phosphate to glucose 6-phosphate in both directions), are not utilized as regulatory control points.

    • Regulation is concentrated exclusively on the two unidirectional, rate-limiting enzymes of glycogen turnover:

      • Glycogen phosphorylase: The primary enzyme responsible for catalyzing the phosphorolytic cleavage and removal of individual glucose residues from glycogen chains.

      • Glycogen synthase: The primary enzyme responsible for catalyzing the addition of glucosyl residues to elongate glycogen chains.

  • The aa and bb nomenclature system:

    • Glycogen phosphorylase was one of the earliest enzymes purified and biochemically characterized, establishing an alphabetic naming convention that was subsequently extended to glycogen synthase:

      • aa form: Denotes the catalytically active state of the enzyme.

      • bb form: Denotes the catalytically inactive (or less active) state of the enzyme.

    • Enzyme interconversion between the inactive bb state and the active aa state is governed reversibly by covalent phosphorylation and dephosphorylation.

  • Upstream regulatory inputs:

    • Hormonal signaling cascades, including insulin, glucagon, and epinephrine, control the directional shift between the aa and bb states to coordinate systemic carbohydrate metabolism.

Regulation of Glycogen Phosphorylase

  • Functional objective during insulin signaling:

    • High circulating blood glucose stimulates insulin secretion to promote glucose uptake, clearance, and storage.

    • To direct glucose into glycogen storage, glycogen phosphorylase must be kept in its inactive bb conformation to prevent premature breakdown.

  • Covalent modification mechanism:

    • Interconversion between the aa and bb forms is driven by reversible phosphorylation at a specific serine residue on the enzyme.

    • Phosphorylated serine: Converts the enzyme into the active conformation, termed glycogen phosphorylase aa.

    • Dephosphorylated serine: Converts the enzyme into the inactive conformation, termed glycogen phosphorylase bb.

  • Enzymes controlling the phosphorylation state of glycogen phosphorylase:

    • Protein Phosphatase 1 (PP1):

      • Historically designated as phosphorylase phosphatase due to its direct dephosphorylation of glycogen phosphorylase.

      • Removes the phosphate group from the serine residue of glycogen phosphorylase aa, converting it into the inactive bb form.

      • PP1 is the identical phosphatase that regulates reciprocal control in glycolysis and gluconeogenesis, providing unified enzymatic control across all carbohydrate pathways.

    • Phosphorylase bb kinase:

      • The dedicated kinase that transfers a phosphate group onto the serine residue of glycogen phosphorylase bb, converting it into the active aa form.

  • Physiological activation conditions:

    • Glycogen phosphorylase is activated when the body requires rapid energy mobilization and increased blood sugar.

    • Glucagon signaling: Secreted during fasting or starvation states, targeting hepatic receptors to stimulate glycogen mobilization.

    • Epinephrine signaling: Released during acute stress (fight-or-flight response), targeting both hepatic and skeletal muscle receptors to trigger immediate fuel breakdown.

  • Receptor binding and cascade amplification:

    • Both glucagon and epinephrine bind to cell surface G-protein coupled receptors (GPCRs / G protein cell receptors).

    • Hormone binding induces an allosteric conformational change in the GPCR, activating intracellular signaling.

    • Signal amplification occurs through second-messenger intermediates: a single activated Protein Kinase A (PKA) enzyme activates multiple phosphorylase bb kinase enzymes.

    • Each activated phosphorylase bb kinase enzyme subsequently phosphorylates and activates multiple glycogen phosphorylase molecules, enabling rapid, high-capacity phosphorolysis of glycogen.

Glucose Sensing Mechanism of Glycogen Phosphorylase

  • Autonomous glucose-sensing function:

    • Glycogen phosphorylase possesses an intrinsic sensory capacity that allows elevated intracellular glucose to directly facilitate the shutoff of its own catalytic activity.

  • Mechanism in hepatic cells:

    • During active glycogenolysis, liver cells generate free glucose and export it across the plasma membrane into the bloodstream via facilitated transport down a concentration gradient.

    • When blood glucose concentrations rise (such as following dietary carbohydrate intake), the trans-membrane concentration gradient diminishes.

    • Because the concentration gradient flattens, facilitated export of glucose from the liver cell slows, causing intracellular free glucose levels to accumulate.

  • Allosteric conformational response to glucose binding:

    • Accumulated intracellular glucose binds to an allosteric inhibitory site on glycogen phosphorylase aa.

    • Glucose binding triggers a conformational shift that causes the phosphorylated serine residues to swing outward from the interior of the protein.

    • This conformational change exposes the attached phosphate groups directly to the aqueous solvent.

    • The exposed phosphate groups become accessible substrates for Protein Phosphatase 1 (PP1).

    • PP1 rapidly hydrolyzes and removes the exposed phosphates, converting glycogen phosphorylase aa to the inactive bb form and terminating glycogen degradation.

Regulation of Glycogen Synthase

  • Nomenclature and activity states:

    • Glycogen synthase conforms to the aa and bb nomenclature:

      • Glycogen synthase aa: The unphosphorylated, catalytically active conformation.

      • Glycogen synthase bb: The phosphorylated, catalytically inactive conformation.

  • Inverted logic of covalent phosphorylation:

    • Unlike glycogen phosphorylase, phosphorylation inhibits glycogen synthase activity.

    • The unphosphorylated state is catalytically active; the phosphorylated state is catalytically inactive.

    • This inverse relationship ensures reciprocal control: adding phosphate groups simultaneously turns on glycogen breakdown (activating phosphorylase) and turns off glycogen synthesis (inactivating synthase). Removing phosphate groups achieves the exact opposite.

  • Activation pathways:

    • Insulin signaling stimulates Protein Phosphatase 1 (PP1).

    • Active PP1 removes the inhibitory phosphate groups from glycogen synthase bb, shifting it to the active aa form to drive glycogenesis.

    • Allosteric activation: Glucose 6-phosphate acts as a positive allosteric regulator. Elevated intracellular glucose 6-phosphate binds to glycogen synthase, stimulating its activity to accelerate the conversion of excess carbohydrate into glycogen.

  • Inactivation pathways and kinase cooperative mechanism:

    • Glucagon and epinephrine signaling promote the inactivation of glycogen synthase to prevent futile synthesis during energy mobilization.

    • Two distinct kinases operate in sequence to transition glycogen synthase from the active aa form to the inactive bb form:

      • Casein kinase 2 (CK2):

        • Acts as a priming kinase by adding an initial set of phosphate groups onto glycogen synthase.

        • Phosphorylation by CK2 does not directly suppress enzymatic activity; instead, it pre-conditions and primes the enzyme structure to generate a binding recognition site for the downstream regulatory kinase.

      • Glycogen synthase kinase 3 (GSK3 / GST3):

        • The primary regulatory kinase that adds the inhibitory phosphate groups to convert primed glycogen synthase from the active aa form to the inactive bb form.

        • In hepatic tissue, GSK3 / GST3 maintains constitutive basal activity unless actively inhibited.

        • Insulin signaling exerts dual control over this mechanism: it activates PP1 to remove phosphates from glycogen synthase while simultaneously transmitting inhibitory signals to shut down GSK3 / GST3, preventing re-phosphorylation and locking glycogen synthase in the active state.

Integrated Hormonal Signaling Cascades

  • Core metabolic junction:

    • Reciprocal regulation controls the bidirectional metabolic axis between glucose 1-phosphate and polymeric glycogen:

      • Glucose 1-phosphate→Glycogen\text{Glucose 1-phosphate} \rightarrow \text{Glycogen}: Driven by active glycogen synthase during periods of glucose abundance.

      • Glycogen→Glucose 1-phosphate\text{Glycogen} \rightarrow \text{Glucose 1-phosphate}: Driven by active glycogen phosphorylase during energy demand (glycogenolysis).

  • Insulin-mediated signaling coordination:

    • Insulin stimulates Protein Phosphatase 1 (PP1).

    • PP1 removes phosphate groups from glycogen phosphorylase, inactivating it and shutting down glycogen breakdown.

    • PP1 removes phosphate groups from glycogen synthase, activating it and stimulating glycogen synthesis.

    • Concurrently, insulin signaling stimulates glycolysis to promote cellular glucose utilization.

  • Glucagon and epinephrine signaling cascades:

    • Glucagon (in liver) and epinephrine (in liver and muscle) bind to G-protein coupled receptors.

    • Activated receptors stimulate adenylyl cyclase to synthesize cyclic AMP (cAMP\text{cAMP}.

    • Elevated cAMP\text{cAMP} activates Protein Kinase A (PKA).

    • PKA phosphorylates and activates phosphorylase bb kinase.

    • Phosphorylase bb kinase phosphorylates glycogen phosphorylase, converting it to the active aa form to initiate glycogenolysis.

    • Downstream kinases concomitantly phosphorylate glycogen synthase, converting it into the inactive bb form.

    • In hepatic tissue, glucagon signaling simultaneously downregulates glycolysis and stimulates gluconeogenesis to favor glucose production and export.

Tissue-Specific Fates of Glycogen Breakdown: Muscle vs. Liver

  • Receptor profiles across tissue types:

    • Skeletal muscle cells: Express epinephrine receptors but lack glucagon receptors; muscle tissue does not respond to starvation signaling via glucagon.

    • Liver cells (hepatocytes): Express both glucagon receptors and epinephrine receptors, responding to systemic nutritional depletion as well as acute stress.

  • Metabolic fate of glycogen in skeletal muscle:

    • Epinephrine stimulation activates glycogen phosphorylase, cleaving glycogen into glucose 1-phosphate.

    • Phosphoglucomutase converts glucose 1-phosphate into glucose 6-phosphate.

    • Skeletal muscle retains glucose 6-phosphate internally, channeling it directly into glycolysis to synthesize ATP\text{ATP} for actomyosin contractile work.

    • Muscle tissue does not express glucose 6-phosphatase; it retains its carbohydrate stores strictly for internal metabolic demands.

  • Metabolic fate of glycogen in the liver:

    • Hormonal stimulation by either glucagon or epinephrine activates glycogenolysis, generating glucose 1-phosphate, which is converted to glucose 6-phosphate.

    • The primary role of hepatic glycogen breakdown is altruistic: maintaining systemic blood glucose concentration to supply peripheral tissues, such as the brain and contracting muscle.

    • Hepatocytes catalyze the terminal reaction of gluconeogenesis using the enzyme glucose 6-phosphatase, which dephosphorylates glucose 6-phosphate to yield free glucose.

    • Free glucose exits the hepatocyte into the systemic circulation via facilitated transport.

    • While glycogen is degraded and free glucose is exported, intrahepatic glycolysis remains downregulated.

Questions and Discussion

  • Closing Session Inquiry:

    • Open prompt: "Alright. So any questions about this?"

    • Context: Concluding query marking the transition from the discussion of reciprocal hormonal regulation, glycogen storage enzymes, and tissue-specific metabolic fates.